Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc.
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | HER2-positive Gastric Cancer | Active, not recruiting | Phase 2 | 2022-09-08 | NCT05190445 |